- Home
- PULM vs CMMB Comparison
PULM vs CMMB Comparison
Compare PULM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | CMMB |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 11.2M |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PULM | CMMB |
|---|---|---|
| Price | $1.26 | $1.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 32.5K | ★ 35.5K |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.18 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $7,910,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $36.50 |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.16 | $0.87 |
| 52 Week High | $9.37 | $3.86 |
Technical Indicators
Market Signals| Indicator | PULM | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 37.56 |
| Support Level | $1.18 | $1.41 |
| Resistance Level | $1.46 | $1.64 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 33.33 | 12.50 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.